Found: 14
Select item for more details and to access through your institution.
TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression.
- Published in:
- Clinical & Translational Immunology, 2022, v. 11, n. 1, p. 1, doi. 10.1002/cti2.1371
- By:
- Publication type:
- Article
P-005: Novel strategy of elotuzumab and zoledronic acid with Th1-like γδT cells against myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S41, doi. 10.1016/S2152-2650(21)02139-X
- By:
- Publication type:
- Article
Synergistic targeting of Sp1 in myeloma cells with hyperthermia plus proteasome inhibitors.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e132, doi. 10.1016/j.clml.2019.09.219
- By:
- Publication type:
- Article
A progressive auto-amplification loop in TAK1 expression and activation in myeloma cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e111, doi. 10.1016/j.clml.2019.09.183
- By:
- Publication type:
- Article
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e105, doi. 10.1016/j.clml.2019.09.173
- By:
- Publication type:
- Article
Inflammatory Cytokine-Induced Muscle Atrophy and Weakness Can Be Ameliorated by an Inhibition of TGF-β-Activated Kinase-1.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 11, p. 5715, doi. 10.3390/ijms25115715
- By:
- Publication type:
- Article
Osteocytes and Paget's Disease of Bone.
- Published in:
- Current Osteoporosis Reports, 2024, v. 22, n. 2, p. 266, doi. 10.1007/s11914-024-00863-5
- By:
- Publication type:
- Article
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon‐α and ATRA.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 969, doi. 10.1111/bjh.15673
- By:
- Publication type:
- Article
Pim‐2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 4, p. 581, doi. 10.1111/bjh.14388
- By:
- Publication type:
- Article
Unique anti‐myeloma activity by thiazolidine‐2,4‐dione compounds with Pim inhibiting activity.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 2, p. 246, doi. 10.1111/bjh.15033
- By:
- Publication type:
- Article
Persistent Activation of Calcium‐Sensing Receptor Suppresses Bone Turnover, Increases Microcracks, and Decreases Bone Strength.
- Published in:
- JBMR Plus, 2019, v. 3, n. 7, p. N.PAG, doi. 10.1002/jbm4.10182
- By:
- Publication type:
- Article
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors.
- Published in:
- International Journal of Hematology, 2023, v. 118, n. 1, p. 88, doi. 10.1007/s12185-023-03601-2
- By:
- Publication type:
- Article
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 929, doi. 10.3390/cancers12040929
- By:
- Publication type:
- Article
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.
- Published in:
- Antioxidants, 2023, v. 12, n. 1, p. 133, doi. 10.3390/antiox12010133
- By:
- Publication type:
- Article